Vasoactive Drug Therapy in Sepsis

  • K. Reinhart
  • F. Bloos
  • C. Spies
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 19)


The hemodynamic alterations of septic shock may impair the determinants of cellular O2 supply on all levels. First, myocardial depression and peripheral vasodilation may result in inadequate perfusion pressure and global O2 transport. Second, the distribution of regional blood flow may be mismatched in the face of changes in the regional metabolic demands (i. e. the hepato-splanchnic region). Third, microvascular blood flow and the tissue’s O2 extraction capability may be disturbed for various reasons. The aim of vasoactive drug therapy in septic shock is therefore to correct the cardiocirculatory alterations as far as possible in order to achieve adequate tissue oxygenation. It has to be stressed however that the basic concept for therapy of septic shock is an adequate fluid resuscitation which never can be replaced by any vasoactive drug therapy.


Nitric Oxide Septic Shock Septic Patient Pulmonary Capillary Wedge Pressure Adult Respiratory Distress Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hayes MA, Yau EH, Timmins AC, Hinds CJ, Watson D (1993) Response of critically ill patients to treatment aimed at achieving supranormal oxygen delivery and consumption. Relationship to outcome. Chest 103: 886–895PubMedCrossRefGoogle Scholar
  2. 2.
    Benedict CR, Grahame-Smith DG (1978) Plasma noradrenaline and adrenaline con-centrations in dopamine-beta-hydroxilase activity in patients with shock due to septicaemia, trauma and hemorrhage. Q J Med 47: 1–20PubMedGoogle Scholar
  3. 3.
    Rooke GA, Feigl EO (1982) Work as a correlate of canine left ventricular oxygen consumption, and the problem of catecholamine oxygen wasting effect. Circ Res 50: 273–286PubMedGoogle Scholar
  4. 4.
    Regan CJ, Duckworth R, Fairhurst JA, Maycock PF, Frayn KN, Campbell IT (1990) Metabolic effects of low-dose dopamine infusion in normal volunteers. Clin Sei 79: 605–611Google Scholar
  5. 5.
    Silverman HJ, Tuma P (1992) Gastric tonometry in patients with sepsis. Effects of do- butamine infusion and packed red blood cell transfusion. Chest 102: 184–188PubMedCrossRefGoogle Scholar
  6. 6.
    Edwards JD, Tweedle DE (1986) The haemodynamic effects of dopamine in severe human shock. Br J Surg 73: 503 (Abst)Google Scholar
  7. 7.
    Vincent JL, Preiser JC (1993) Inotropic agents. New Horizons 1: 137–144PubMedGoogle Scholar
  8. 8.
    Goldberg LI (1972) Cardiovascular and renal actions of dopamine. Potential clinical applications. Pharmacol Rev 24: 1–29PubMedGoogle Scholar
  9. 9.
    Wilson RF, Sibbald WJ, Jaanimagi JL (1976) Hemodynamic effects of dopamine in critically ill patients. J Surg Res 20: 163–172PubMedCrossRefGoogle Scholar
  10. 10.
    Fleckenstein W, Reinhart K, Kersting T, et al (1984) Dopamine effects on the oxygenation of human skeletal muscle. Adv Exp Med Biol 180: 609–613PubMedGoogle Scholar
  11. 11.
    Shoemaker WC, Appell PL, Kram HB, Duarte D, Harrier HD, Ocampo HA (1989) Comparison of hemodynamic and oxygen transport effects of dopamine and dobutam- ine in critically ill surgical patients. Chest 96: 120–126PubMedCrossRefGoogle Scholar
  12. 12.
    Regnier B, Safan D, Carlot J, et al (1979) Comparative haemodynamic effects of dopamine and dobutamine in septic shock. Intensive Care Med 5: 115–119PubMedCrossRefGoogle Scholar
  13. 13.
    Vincent JL, van der Linden P, Domb M, Blecic S, Azimi G, Bernard A (1987) Dopamine compared with dobutamine in experimental septic shock: Relevance to fluid administration. Anesth Analg 66: 565–571PubMedCrossRefGoogle Scholar
  14. 14.
    Shoemaker WC, Appel PL, Kram HB (1991) Oxygen transport measurements to evaluate tissue perfusion and titrate therapy: Dobutamine and dopamine effects. Crit Care Med 19: 672–688PubMedCrossRefGoogle Scholar
  15. 15.
    Ruokonen E, Takala J, Kari A, Saxen H, Mertsola J, Hansen EJ (1993) Regional blood flow and oxygen transport in septic shock. Crit Care Med 21: 296–303CrossRefGoogle Scholar
  16. 16.
    Meier-Hellmann A, Reinhart K (1994) Influence of catecholamines on regional perfusion and tissue oxygenation in septic shock patients. In: Reinhart K, Eyrich K, Sprung C (eds) Sepsis: Current perspectives in pathophysiology and therapy. Springer-Verlag, Berlin, Heidelberg, New York, pp 274–291Google Scholar
  17. 17.
    Pawlik W, Shepherd AD, Jacobson ED (1975) Effects of vasoactive agents on intestinal oxygen consumption and blood flow in dogs. J Clin Invest 56: 484–490PubMedCrossRefGoogle Scholar
  18. 18.
    Roytblat L, Gelman S, Bradley EL, Henderson T, Parks D (1990) Dopamine and hepatic oxygen supply-demand relationship. Can J Physiol Pharmacol 68: 1165–1169PubMedCrossRefGoogle Scholar
  19. 19.
    Mousdale S, Clyburn PA, Mackie AM, Groves ND, Rosen M (1988) Comparison of the effects of dopamine, dobutamine, and dopexamine upon renal blood flow: A study in normal healthy volunteers. Br J Clin Pharmacol 25: 555–560PubMedGoogle Scholar
  20. 20.
    Schaer GL, Fink MP, Parrillo JE (1985) Norepinephrine alone versus norepinephrine plus low-dose dopamine: Enhanced renal blood flow with combination pressor therapy. Crit Care Med 13: 492–496PubMedCrossRefGoogle Scholar
  21. 21.
    Zaritsky A, Horowitz M, Chernow B (1988) Complications of the pharmacotherapy of septic shock. In: Lumb PD, Bryan-Brown CW (eds) Complications in critical care medicine. Year Book Medical Publishers, Chicago, pp 66–80Google Scholar
  22. 22.
    van Trigt P, Spray TL, Pasque MK, Peyton RB, Pellom GL, Wechsler AS (1984) The comparative effects of dopamine and dobutamine on ventricular mechanics after coronary artery bypass grafting: A pressure-dimension analysis. Circulation 70 (Suppl I): I112–I117Google Scholar
  23. 23.
    Leier CV, Underferth DV (1983) Dobutamine. Ann Int Med 99: 490–496Google Scholar
  24. 24.
    Shoemaker WC, Appel PL, Kram HB (1986) Haemodynamic and oxygen transport effects of dobutamine in critically ill general surgical patients. Crit Care Med 14: 1032–1037PubMedCrossRefGoogle Scholar
  25. 25.
    Jardin F, Spomche M, Bazine M (1981) Dobutamine: A haemodynamic evaluation in human septic shock. Crit Care Med 9: 329–333PubMedCrossRefGoogle Scholar
  26. 26.
    Vincent JL, Roman A, Kahn RJ (1990) Dobutamine administration in septic shock: Addition to a standard protocol. Crit Care Med 18: 689–693PubMedCrossRefGoogle Scholar
  27. 27.
    Vincent JL, Roman A, de Backer D, Kahn RJ (1990) Oxygen uptake/supply dependency. Effects of short-term dobutamine infusion. Am Rev Respir Dis 142: 2–7PubMedGoogle Scholar
  28. 28.
    Schneider AJ, Groeneveld ABJ, Teule GJJ, Nauta J, Heidendal GAK, Thijs LG (1987) Volume expansion, dobutamine and noradrenaline for treatment of right ventricular dysfunction in porcine septic shock: A combined invasive and radionuclide study. Circ Shock 23: 93–106PubMedGoogle Scholar
  29. 29.
    Lam C, Tyml K, Martin C, Sibbald WJ (1991) The skeletal muscle microcirculation in sepsis. Microcirc Res 15: A113 (Abst)Google Scholar
  30. 30.
    Dasta JF (1990) Norepinephrine in septic shock: Renewed interest in an old drug. Ann Pharmacother 24: 153–156Google Scholar
  31. 31.
    Sprecht M, Meier-Hellmann A, Hannemann L, et al (1993) Effects of dobutamine vs norepinephrine therapy on oxygen supply and oxygen consumption in septic patients. Crit Care Med 21 (Suppl): S276 (Abst)CrossRefGoogle Scholar
  32. 32.
    Desjars P, Pinaud M, Potel G, Tasseau F, Touze MD (1987) A reappraisal of norepi-nephrine in human septic shock. Crit Care Med 15: 134–137PubMedCrossRefGoogle Scholar
  33. 33.
    Hesselvik JF, Brodin B (1989) Low dose norepinephrine in patients with septic shock and oliguria: Effects on afterload, urine flow, and oxygen transport. Crit Care Med 17: 179–180PubMedCrossRefGoogle Scholar
  34. 34.
    Fellows IW, Bennett T, MacDonald IA (1985) The effect of adrenaline upon cardiovascular and metabolic function in man. Clin Sei 69: 215–222Google Scholar
  35. 35.
    Lipman J, Roux J, Kraus P (1991) Vasoconstrictor effects of adrenaline in human septic shock. Anaesth Intens Care 19: 61–65Google Scholar
  36. 36.
    Moran JL, O’Fathartaigh MS, Peisach AR, Chapman MJ, Leppard P (1993) Epinephrine as an inotropic agent in septic shock: A dose-profile analysis. Crit Care Med 21: 70–77PubMedCrossRefGoogle Scholar
  37. 37.
    Mackenzie SJ, Kapadia F, Nimmo GR, Armstrong IR, Grant IS (1991) Adrenaline in treatment of septic shock: Effects on haemodynamics and oxygen transport. Intensive Care Med 17: 36–39PubMedCrossRefGoogle Scholar
  38. 38.
    Wilson W, Lipman J, Scribante J, et al (1992) Septic shock: Does adrenaline have a role as a first line inotropic agent? Anaesth Intens Care 20: 470–474Google Scholar
  39. 39.
    Giraud GD, MacCannell KL (1984) Decreased nutrient blood flow during dopamine - and epinephrine-induced intestinal vasodilation. J Pharmacol Exp Ther 230: 214–220PubMedGoogle Scholar
  40. 40.
    Meier-Hellmann A, Specht M, Spies C, Larscheid P, Bartels K, Reinhart K (1994) Impairment of splanchnic perfusion and tissue oxygenation by epinephrine in patients with septic shock. Clin Int Care 5 (Suppl): 23 (Abst)Google Scholar
  41. 41.
    Bollaert PE, Bauer P, Audibert G, Lambert H, Larcan A (1990) Effects of epinephrine on hemodynamics and oxygen metabolism in dopamine-resistant septic shock. Chest 98: 949–953PubMedCrossRefGoogle Scholar
  42. 42.
    Gregory JS, Bonfiglio MF, Dasta JF, Reilley TE, Townsend MC, Flancbaum L (1991) Experience with phenylephrine as a component of the pharmacologic support of septic shock. Crit Care Med 19: 1395–1400PubMedCrossRefGoogle Scholar
  43. 43.
    Bonfiglio MF, Dasta JF, Gregory JS, Townsend MC, Reilly TE, Flancbaum L (1990) High-dose phenylephrine infusion in the hemodynamic support of septic shock. Ann Pharmacother 24: 936–939Google Scholar
  44. 44.
    Lokhandwala MF, Jandhyala BS (1992) Effects of dopaminergic agonists on organ blood flow and function. Clin Int Care 3 (Suppl): 12–16Google Scholar
  45. 45.
    Leier CV (1988) Regional blood flow responses to vasodilators and inotropes in congestive heart failure. Am J Cardiol 62: 86E–93EPubMedCrossRefGoogle Scholar
  46. 46.
    Colardyn FC, Vandenbogaerde JF, Vogelaers DP, Verbeke JH (1989) Use of dopexamine hydrochloride in patients with septic shock. Crit Care Med 17: 999–1003PubMedCrossRefGoogle Scholar
  47. 47.
    Boyd O, Grounds RM, Bennett ED (1993) A randomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA 270: 2699–2707PubMedCrossRefGoogle Scholar
  48. 48.
    Bredle DL, Cain SM (1991) Systemic and muscle oxygen uptake/delivery after dopex- amine infusion in endotoxic dogs. Crit Care Med 19: 198–204PubMedCrossRefGoogle Scholar
  49. 49.
    Webb AR, Moss RF, Tighe D, al-Saady N, Bennett ED (1991) The effects of dobutam- ine, dopexamine and fluid on hepatic histological responses to porcine faecal peritonitis. Intensive Care Med 17: 487–493PubMedCrossRefGoogle Scholar
  50. 50.
    Cain SM, Curtis SE (1991) Systemic and regional oxygen uptake and delivery and lactate flux in endotoxic dogs infused with dopexamine. Crit Care Med 19: 1552–1560PubMedCrossRefGoogle Scholar
  51. 51.
    van Lambalgen AA, van Kraats A A, Mulder MF, van den Bos GC, Teerlink T, Thijs LG (1993) Organ blood flow and distribution of cardiac output in dopexamine- or do- butamine-treated endotoxemic rats. J Crit Care 8: 117–127PubMedCrossRefGoogle Scholar
  52. 52.
    Steinberg SM, Dehring D, Gower WR, Vento JM, Lowery BD, Cloustier CT (1983) Prostacyclin in experimental septic acute respiratory failure. J Surg Res 34: 298–302PubMedCrossRefGoogle Scholar
  53. 53.
    Öwall A, Davilen J, Sollevi A (1991) Influence of adenosine and prostacyclin on hy- poxia-induced pulmonary hypertension in the anaesthetized pig. Acta Anaesthesiol Scand 35: 350–354PubMedCrossRefGoogle Scholar
  54. 54.
    Slotman G, Machiedo G, Casey K, Lyons M (1982) Histological and haemodynamic effects of prostacyclin and prostaglandin Ex following oleic acid infusion. Surgery 92: 93PubMedGoogle Scholar
  55. 55.
    Utsunomiya T, Krausz MM, Kobayashi M, Shepro D. Hechtman HB (1982) Myocardial protection with prostacyclin after lethal endotoxemia. Surgery 92: 101–108PubMedGoogle Scholar
  56. 56.
    Fletcher JR, Raumwell PW (1980) The effects of prostacyclin (PGI2) on endotoxic shock and endotoxin-induced platelet aggregation in dogs. Circ Shock 7: 299–308PubMedGoogle Scholar
  57. 57.
    Rubin LJ, Mendoza J, Hood M, et al. (1990) Treatment of primary pulmonary hypertension with continuous intravenous of prostacyclin (epoprostenol), resulsts of a randomized trial. Ann Int Med 112: 485–491PubMedGoogle Scholar
  58. 58.
    Jones K, Higenbottam T, Wallwork MB (1989) Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. Chest 96: 784–789PubMedCrossRefGoogle Scholar
  59. 59.
    Shoemaker WC, Appel PL (1985) Effects of prostaglandin Ei in adult respiratory distress syndrome. Surgery 99: 275–283Google Scholar
  60. 60.
    Holcroft JW, Vassar MJ, Weber CJ (1985) Prostaglandin Ei and survival in patients with the adult respiratory distress syndrome. Ann Surg 203: 371–378CrossRefGoogle Scholar
  61. 61.
    Bone RC, Slotman G, Maunder R, et al (1989) Randomized double-blind, multicenter study of prostaglandin Ex in patients with the adult respiratory distress syndrome. Chest 96: 114–119PubMedCrossRefGoogle Scholar
  62. 62.
    Silverman HJ, Slotman G, Bone RC, et al (1990) Effects of prostaglandin Li on oxygen delivery and consumption in patients with adult respiratory distress syndrome. Chest 98: 405–410PubMedCrossRefGoogle Scholar
  63. 63.
    Pittet JF, Lacroix JS, Gunning K, Laverriere MC, Morel DR, Suter PM (1990) Prostacyclin but not phentolamine increases oxygen consumption and skin microvascular blood flow in patients with sepsis and respiratory failure. Chest 98: 1467–1472PubMedCrossRefGoogle Scholar
  64. 64.
    Bihari D, Smithies M, Grimson A, Tinker J (1987) The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients. N Engl J Med 317: 397–403PubMedCrossRefGoogle Scholar
  65. 65.
    De Backer D, Berre J, Zhang H, Kahn R, Vincent JL (1993) Relationship between oxygen uptake and oxygen delivery in septic patients: Effects of prostacyclin versus dobutamine. Crit Care Med 21 1659–1664CrossRefGoogle Scholar
  66. 66.
    Radermacher P, Buhl R, Kemnitz J, et al (1993) Prostacyclin improves gastric mucosal pH in patients with septic shock. Clin Int Care 4: 9Google Scholar
  67. 67.
    Palmer RMJ, Ferrige AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524–526PubMedCrossRefGoogle Scholar
  68. 68.
    Wright C, Rees D, Moncada S (1992) Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 26: 48–57PubMedCrossRefGoogle Scholar
  69. 69.
    Myers PR, Minor RL Jr, Guerra R Jr, et al (1990) Vasorelaxant properties of the en-dothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 345: 161–163PubMedCrossRefGoogle Scholar
  70. 70.
    Harrison PM, Wendon JA, Gimson AES, et al (1991) Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 324: 1852–1857PubMedCrossRefGoogle Scholar
  71. 71.
    Spies C, Reinhart K, et al (1994) Influence of N-Acetylcysteine on 02 consumption and gastric intramucosal pH in septic patients. Crit Care Med (in press)Google Scholar
  72. 72.
    Bernard GR, Swindell BB, Meredith MJ, et al (1989) Glutathione repletion by N-ace- tylcysteine (NAC) in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 139: A221 (Abs)Google Scholar
  73. 73.
    Fiddian-Green RG (1993) Associations between intramucosal acidosis in the gut and organ failure. Crit Care Med 21: S103–S107PubMedCrossRefGoogle Scholar
  74. 74.
    Zhang H, Spapen H, Nguyen DN, Benlabed M, Buurman WA, Vincent JL (1994) Pro-tective effects of N-acetylcysteine in endotoxemia. Am J Physiol (in press) 266:H1746–H1754Google Scholar
  75. 75.
    Brigham KL (1991) Oxygen radicals - an important mediator of sepsis and septic shock. Klin Wochenschr 69: 1004–1008PubMedCrossRefGoogle Scholar
  76. 76.
    Boyd O, Bennett ED (1992) Is oxygen consumption an important clinical target? In: Vincent JL (ed): Yearbook of Intensive Care and Emergency Medicine. Springer, Berlin pp 310–324Google Scholar
  77. 77.
    Ochoa JB, Ukdekwu AO, Billiar TR, et al (1991) Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 214: 621–626PubMedCrossRefGoogle Scholar
  78. 78.
    Petros A, Bennett D, Vallance P (1991) Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338: 1557–1558PubMedCrossRefGoogle Scholar
  79. 79.
    Freund H, Atamian S, Holroyde J, et al (1979) Plasma amino acids as predictors of the severity and outcome of sepsis. Ann Surg 190: 571–576PubMedCrossRefGoogle Scholar
  80. 80.
    Meyer J, Traber LD, Nelson S, et al (1992) Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 73: 324–328PubMedGoogle Scholar
  81. 81.
    Finkel MS, Oddis CV, Jacob TD, et al (1992) Negative inotropic effects of cytokines on the mediated by nitric oxide. Science 257: 387–389PubMedCrossRefGoogle Scholar
  82. 82.
    Estrada C, Gomez C, Martin C, et al (1992) Nitric oxide mediates tumor necrosis fac- tor-a cytotoxicity in endothelial cells. Biochem Biophys Res Commun 186: 475–482PubMedCrossRefGoogle Scholar
  83. 83.
    Hughes SR, Williams TJ, Brain SD, et al (1990) Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. Eur J Pharmacol 191: 481–484PubMedCrossRefGoogle Scholar
  84. 84.
    Bernard GR, Lucht WD, Niedermeyer ME, et al (1984) Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J Clin Invest 73: 1772–1784PubMedCrossRefGoogle Scholar
  85. 85.
    Chaterjee K (1988) Enoximone in heart failure: Mechanisms of action. Br J Clin Pract 64: 19–25Google Scholar
  86. 86.
    Vincent JL, Carlier E, Berre J, et al (1988) Administration of enoximone in cardiogenic shock. Am J Cardiol 62: 419–423PubMedCrossRefGoogle Scholar
  87. 87.
    Gage J, Rutman H, Lucido D, et al (1986) Additive effects of dobutamine and amri- none on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74: 367–373PubMedCrossRefGoogle Scholar
  88. 88.
    De Boelpape C, Vincent JL, Contempre B (1989) Combination of norepinephrine and amrinone in the treatment of endotoxin shock. J Crit Care 4: 202–207CrossRefGoogle Scholar
  89. 89.
    Vincent JL, Domb M, van der Linden P, et al (1988) Amrinone administration in endotoxic shock. Circ Shock 26: 75–83Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • K. Reinhart
  • F. Bloos
  • C. Spies

There are no affiliations available

Personalised recommendations